Patterns of drug treatment for manic episode in the clinical practice. Outcomes of the Spanish sample in the EMBLEM Study

Actas Espanolas de Psiquiatria

Volumn 35, Issue 5, 2007, Pages 315-322

  Montoya, Alonso ^a   Perez Sanchez Toledo J ^b   Gilaberte, I ^a   Gonzalez Pinto A ^c,g   Haro, J M ^d,g   Vieta, E ^e,g   Tohen, M ^f  

^a ELI LILLY AND COMPANY   (Spain)

^b UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^c HOSPITAL TXAGORRITXU   (Spain)

^d Centre de Salut Mental El Prat   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

^f HARVARD MEDICAL SCHOOL   (United States)

^g Red de Enfermedades Mentales REM TAP ^*  (Spain)

Author keywords

Bipolar disorder; EMBLEM; Mania

Indexed keywords

ADULT; ARTICLE; BIPOLAR DISORDER; CLINICAL PRACTICE; DRUG THERAPY; FEMALE; HUMAN; MALE; METHODOLOGY; SPAIN; STATISTICS;

ADULT; BIPOLAR DISORDER; DRUG THERAPY; FEMALE; HUMANS; MALE; PHYSICIAN'S PRACTICE PATTERNS; SPAIN;

EID: 35948982667     PISSN: 11399287     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Perlis RH, Ostacher MJ, Patel JK, Marangell LB, Zhang H, Wisniewski SR, et al. Predictors of recurrence in bipolar disorder: primary outcomes from the Systematic Treatment Enhancement Program for Bipolar Disorder (STEP-BD). Am J Psychiatry 2006;163:217-24.
2. McElroy SL, Keck PE Jr. Pharmacologie agents for the treatment of acute bipolar mania. Biol Psychiatry 2000;48:539-57.
3. Kupfer DJ, Frank E, Grochocinski VJ, Cluss PA, Houck PR, Stapf DA. Demographic and clinical characteristics of individuals in a bipolar disorder case registry. J Clin Psychiatry 2002;63:120-5.
4. Bridle C, Palmer S, Bagnall AM, Darba J, Duffy S, Sculpher M, et al. A rapid and systematic review and economic evaluation of the clinical and cost-effectiveness of newer drugs for treatment of mania associated with bipolar affective disorder. Health Technol Assess 2004;8:iii-iv, 1-187.
5. Mensink GJ, Slooff CJ. Novel antipsychotics in bipolar and schizoaffective mania. Acta Psychiatr Scand 2004;109:405-19.
6. Soldani F, Ghaemi SN, Baldessarini RJ. Research reports on treatments for bipolar disorder: preliminary assessment of methodological quality. Acta Psychiatr Scand 2005;112:72-4.
7. Vieta E, Carne X. The use of placebo in clinical trials on bipolar disorder: a new approach for an old debate. Psychother Psychosom 2005;74:10-6.
8. Haro JM, Edgell ET, Novick D, Alonso J, Kennedy L, Jones PB, et al; SOHO advisory board. Effectiveness of antipsychotic treatment for schizophrenia: 6-month results of the Pan-European Schizophrenia Outpatient Health Outcomes (SOHO) study. Acta Psychiatr Scand 2005;111:220-31.
9. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005;353:1209-23.
10. Haro JM, Os J, Vieta E, Reed C, Lorenzo M, Goetz I; the EMBLEM Advisory Board. Evidence for three distinct classes of «typical», «psychotic» and «dual» mania: results from the EMBLEM study. Acta Psychiatr Scand 2006;113:112-20.
11. Goetz I, Tohen M, Reed C, Lorenzo M, Vieta E, and the EMBLEM Advisory Board. Functional impairment in patients with mania: baseline results of the EMBLEM study. Bipolar Disord 2007;9:45-52.
12. Vieta E, Torrent C, Martinez-Arán A, Colom F, Reinares M, et al. A user-friendly scale for the short and long term outcome of bipolar disorder: the CGI-BP-M. Actas Esp Psiquiatr 2002;30:301-4.
13. Colom F, Vieta E, Martínez-Arán A, García- García M, Reinares M, Torrent C, et al. Spanish version of a scale for the assessment of mania: validity and reliability of the young mania rating scale. Med Clin (Barc) 2002;119:366-71.
14. González-Pinto A, Ballesteros J, Aldama A, Pérez de Heredia JL, Gutiérrez M, Mosquera F, et al. Principal components of mania. J Affect Disord 2003;76:95-102.
15. Leverich GS, Post RM. The NIMH Life Chart Manual for Recurrent Affective Illness: the LCM. Monograph 1993.
16. Keller MB, Lavori PW, Friedman B, Nielsen E, Endicott J, McDonald-Scott, et al. The longitudinal interval follow-up evaluation. A comprehensive method for assessing outcome in prospective longitudinal studies. Arch Gen Psychiatry 1987;44:540-8.
17. Vieta E, Herraiz M, Parramon G, Goikolea JM, Fernández A, Benabarre A. Risperidone in the treatment of mania: efficacy and safety results from a large, multicentre, open study in Spain. J Affect Disord 2002;72:15-9.
18. Colom F, Vieta E, Sánchez-Moreno J, Martínez-Arán A, Reinares M, Goikolea JM, et al. Stabilizing the stabilizer: group psychoeducation enhances the stability of serum lithium levels. Bipolar Disord 2005;7(Suppl. 5):32-6.
19. Colom F, Lam D. Psychoeducation: improving outcomes in bipolar disorder. Eur Psychiatry 2005;20:359-64.
20. Sajatovic M, Davies M, Hrouda DR. Enhancement of treatment adherence among patients with bipolar disease. Psychiatr Serv 2004;55:264-9.
21. Berk M, Berk L, Castle D. A collaborative approach to the treatment alliance in bipolar disorder. Bipolar Disord 2004;6:504-18.
22. Tohen M, Chengappa KN, Suppes T, Baker RW, Zarate CA, Bowden CL, et al. Relapse prevention in bipolar I disorder: 18 month comparison of olanzapine plus mood stabilizer v. mood stabilizer alone. Br J Psychiatry 2004;184:337-45.
23. Tonen M, Goldberg JF, González-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12 week double blind comparison of olanzapine versus haloperidol in the treatment of acute mania. Arch Gen Psychiatry 2003;60:1218-26.
24. Lin D, Mok H, Yatham LN. Polytherapy in bipolar disorder. CNS Drugs 2006;20:29-42.
25. Hirschfeld RMA, Keck PE, Kramer M, Karcher K, Canuso C, Eerdekens M, et al. Rapid antimanic effect of risperidone monotherapy: a 3 week multicenter, double blind, placebo controlled trial. Am J Psychiatry 2004;161:1057-65.